Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We conducted a phase II study of erlotinib after failure of gefitinib treatment in patients with non-small-cell lung cancer (NSCLC).
introduction
Erlotinib and gefitinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used to treat patients with advanced or metastatic non-small-cell lung cancer (NSCLC). Although their similar structures and mechanism of action suggest that erlotinib and gefitinib should have similar efficacies, the agents have somewhat different pharmacological properties. For example, erlotinib is less susceptible than is gefitinib to metabolism by the cytochrome P450 pathway and therefore has a lower clearance rate and inhibits the activity of wild-type EGFR at lower concentrations than gefitinib [1, 2] . In addition, because the maximumtolerated doses of gefitinib and erlotinib are 1000 and 150 mg, respectively [3, 4] , the usual dose of erlotinib 150 mg may be a higher biological dose than the usual dose of gefitinib 250 mg. These differences may account at least in part for the contradictory results of the two phase III studies, in which erlotinib, but not gefitinib, was found to prolong survival in previously treated patients [5, 6] . These findings suggested that salvage treatment with erlotinib may be an option for patients who fail gefitinib treatment. We therefore carried out a prospective phase II study of erlotinib in patients with advanced or metastatic NSCLC who showed disease progression on gefitinib treatment.
patients and methods eligibility
Patients with advanced or metastatic NSCLC who had documented progressive disease on gefitinib treatment were eligible for inclusion if they had at least one unidimensionally measurable lesion, an Eastern Cooperative Oncology Group performance status of zero to three, and adequate organ functions [white blood cell 3000/ll, platelets 100 000/ll, hemoglobin 9.0 g/dl, serum creatinine 1.5· the upper limit of normal (ULN), bilirubin 1.25· ULN, and serum aminotransferases 2.5· ULN]. Prior chemotherapy or radiotherapy was allowed. Brain metastases were also allowed if they were asymptomatic or controlled by supportive care. However, those patients with unresolved chronic toxicity from prior therapy, other active malignancies, uncontrolled brain metastases, or severe comorbid conditions were excluded. The study was approved by the institutional review board of the Asan Medical Center, and written informed consent was obtained from all enrolled patients. The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. is defined as at least a 30% decrease in the sum of the longest diameter of target lesion, taking as reference the baseline sum longest diameters and/or the persistent of one or more nontarget lesion(s); progressive disease (PD) defined as at least a 20% increase in the sum of the longest diameter taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions; and stable disease (SD) defined as neither sufficient shrinkage to qualify the partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. For patients with documented CR or PR, a confirmatory. Progression-free survival (PFS) was defined as the interval between the date treatment started and the date of documented disease progression or death from any cause. Overall survival (OS) was defined as the interval between the date treatment started and the date of death from any cause. Patients lost to follow-up were censored at the last date of contact. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event version 3.0.
study design

statistical consideration
A Simon two-stage optimal design was chosen for definition of the total number of patients required for the phase II study. We set a response rate of 15% as the target activity level and 5% as the lowest response rate (objective response rate) of interest. The study was designed to have 80% power to accept the hypothesis and 5% significance to reject the hypothesis. For a total of 56 patients, 23 would be accrued during the first stage and 33 during the second stage. If one or no response was observed during the first stage, the study would be stopped early. If five or fewer responses were observed by the end of the study, no further investigation of the drug would be warranted.
patients' characteristics
Between September 2006 and January 2008, a total of 23 patients entered into the study and all were assessable for response and toxicity. All patients were never smokers and all but one had adenocarcinoma histology. Before starting therapy, we knew the mutation status of exons 18-21 of the EGFR gene in 10 patients (43.5%); three had exon 19 deletions, two had exon 18 substitutions, and five had no mutations. Fifteen patients (65.2%) had benefited from prior gefitinib therapy. Patients' characteristics are shown in Table 1 .
response and survival outcome
Out of 23 patients, one had PR and one had SD, giving an overall response rate of 4.3% and a disease control rate of 8.7% (Table 2 ). These two patents were female never smokers with adenocarcinoma histology and both had a best response of OR to prior gefitinib treatment. In the patient with a PR to erlotinib treatment, an interval from discontinuation of gefitinib to administration of erlotinib was 7.4 months, her PFS during gefitinib treatment was 3.9 months, and her PFS during erlotinib treatment was 6.2 months, while in the patient with SD, the corresponding values were 1.4, 12.0, and 7.8 months, respectively. The remaining 21 patients showed PD to erlotinib treatment within 3 months.
toxicity profile
The most common toxic effects were skin rash recorded in 14 patients (60.9%) and diarrhea in seven patients (30.4%). Two patients (8.7%) experienced grade 3 skin rash. Only one patient required a dose reduction of erlotinib due to grade 3 hyperbilirubinemia. discussion Both erlotinib and gefitinib are currently available in Korea and are used to treat patients with advanced or metastatic NSCLC in second-or third-line setting or sometimes in first-line setting for a specific subset of patients [7, 8] . Most patients treated with these agents, however, had progressive disease even after showing an initial dramatic response. Although gefitinib and erlotinib are thought to exhibit cross-resistance, their pharmacological differences as well as their distinct clinical outcomes suggest that erlotinib may be effective after failure of gefitinib treatment [9] [10] [11] [12] . Two studies have shown that erlotinib after failure of gefitinib treatment yielded disease control rates of 35.7% (5 of 14) and 28.6% (6 of 21), respectively, [11, 12] , although other studies, including ours, have shown contradictory results [13] . Of interest, most patients who benefit from erlotinib had also benefited from prior gefitinib treatment (Table 3 ) [9] [10] [11] [12] 14] , including the two patients in our study who benefited from erlotinib. In our study, of the 15 patients who benefited from gefitinib, two benefited from erlotinib treatment, yielding a disease control rate of 13.3% (2 of 15), which, however, was rather lower than those of 55.5 % (5 of 9) and 50.0% (5 of 10) in the prior two studies [11, 12] . This finding suggested that as a salvage treatment after failure of gefitinib treatment, erlotinib should be chosen very carefully in a more highly selective subset of patients. Several explanations could be possible for the responsiveness to erlotinib after failure of gefitinib. Difference in tumor sensitivity, especially wild-type EGFR tumors might be associated with the relative concentration of EGFR TKIs. The IC 50 value of erlotinib is much lower than that of gefitinib [2] and 8 of 10 patients benefiting from erlotinib had wild-type EGFR [14] . Most of these patients, however, had also benefited from prior gefitinib. In contrast, most patients who did not benefit from prior gefitinib treatment did not respond to subsequent erlotinib treatment. Another possibility may be that tumors may possess both EGFR TKI-sensitive and -resistant clones at the beginning of gefitinib treatment. During gefitinib treatment, only EGFR TKI-resistant clones can grow, but after discontinuation of gefitinib therapy and/or during subsequent chemotherapy, sensitive clones may grow faster or survive better than do resistant clones. Thus, subsequent erlotinib therapy could kill such TKI-sensitive clones, similar to the effectiveness sometimes observed following readministration of gefitinib [15] . However, most of our patients had short time intervals from discontinuation of gefitinib to commencement of erlotinib, with some patients starting erlotinib immediately after progression on gefitinib treatment. In addition, response to subsequent chemotherapy was also poor [12, 15] . Finally, some of acquired gefitinib-resistant clones might be nonresistant or incompletely cross-resistant to erlotinib. Among the mechanism of acquired resistance to EGFR TKIs, T790M secondary mutation or amplification of the MET oncogene was reportedly common [16, 17] . However, other secondary mutations have also been reported [18, 19] . Of note, unlike T790M secondary mutation, some mutations, such as L748S or E884K mutation, may result in different sensitivities to gefitinib and erlotinib, resulting in different tumor responses to these two agents [14, 20] . Therefore, although half of patients could overcome the resistant T790M secondary mutation by empirical use of irreversible EGFR TKIs, identification of the mechanism of acquired resistance in each patient could guide the proper use of these two different EGFR TKIs.
In conclusion, our finding suggested that erlotinib should not be given routinely after failure of gefitinib treatment, but may be an option for a more highly selected subset of patients, especially those who had already benefited from prior gefitinib treatment. However, identification of molecular markers in tumors is important to understand and overcome molecular mechanisms of resistance. 
